This study evaluates the long-term RSV burden among pre-term and term infants in the US.
Infants with birth hospitalization claim and ≥24 months of continuous enrollment were retrospectively identified in the Truven MarketScan® Commercial Claims and Encounters database 01JAN04-30SEP2015. Infants with RSV in the first year of life (n=38,473) were matched to controls (n=76,825) and remaining imbalances adjusted using propensity score methodology. All-cause, respiratory- and asthma/wheezing-related 5-year average cumulative costs were measured.
Early premature (n=213), premature (n=397), late premature (n=4446), and full-term (n=33,417) RSV infants were matched to 424, 791, 8875, and 66,735 controls, respectively. At 2-years follow-up, all-cause cumulative costs compared with controls increased by: for early premature, $51,016 (95% CI: $3725, $98,306); premature, $29,226 ($13,285, $45,166); late premature, $11,372 ($9255, $13,490); full-term infants, $6665 ($6301, $7029). The 5-year RSV burden increased to $57,274 (95% CI: $9700, $104,848), $30,484 ($14,400, $46,567), $15,085 ($12,528, $17,643), and $8973 ($8522, $9424), respectively. The RSV burden was higher when stratified by inpatient/outpatient settings and respiratory- and asthma/wheezing-related costs.
The RSV burden extends across cost domains and prematurity with greatest burden incurred by second year of follow-up. Findings are useful in determining the cost-effectiveness of RSV agents in development.